Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma

Journal of the National Cancer Institute

Volumn 106, Issue 9, 2014, Pages

  Liu, Yuexin ^a   Patel, Lalit ^a   Mills, Gordon B ^a   Lu, Karen H ^a   Sood, Anil K ^a   Ding, Li ^b   Kucherlapati, Raju ^c   Mardis, Elaine R ^b   Levine, Douglas A ^d   Shmulevich, Ilya ^e   Broaddus, Russell R ^a   Zhang, Wei ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CYCLIN D1; ESTROGEN RECEPTOR ALPHA; MYC PROTEIN; PROGESTERONE RECEPTOR; TRANSCRIPTOME; CTNNB1 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; COHORT ANALYSIS; ENDOMETRIOID ENDOMETRIAL CARCINOMA; ENDOMETRIUM CARCINOMA; EXON; FEMALE; FOLLOW UP; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; OBESITY; OVERALL SURVIVAL; PRIORITY JOURNAL; REVERSE PHASE PROTEIN ARRAY; RNA SEQUENCE; UPREGULATION; WNT SIGNALING PATHWAY; ADULT; ENDOMETRIOID CARCINOMA; ENDOMETRIUM TUMOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; MUTATION; PATHOLOGY; TISSUE MICROARRAY;

ADULT; BETA CATENIN; CARCINOMA, ENDOMETRIOID; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MUTATION; NEOPLASM GRADING; NEOPLASM STAGING; TISSUE ARRAY ANALYSIS; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL; WNT SIGNALING PATHWAY;

EID: 84909619822     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju245     Document Type: Article

References (25)

1. Siegel R, Naishadham, D, Jemal, A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30.
2. Nagle CM, Marquart, L, Bain, CJ, et al. Impact of weight change and weight cycling on risk of different subtypes of endometrial cancer. Eur J Cancer. 2013;49(12):2717-2726.
3. Salvesen HB, Carter, SL, Mannelqvist, M, et al. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc Natl Acad Sci U S A. 2009;106(12):4834-4839.
4. Maxwell GL, Chandramouli, GV, Dainty, L, et al. Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer. Clin Cancer Res. 2005;11(11):4056-4066.
5. Mutter GL, Baak, JP, Path, FR, et al. Global expression changes of constitutive and hormonally regulated genes during endometrial neoplastic transformation. Gynecol Oncol. 2001;83(2):177-185.
6. TCGA. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67-73.
7. Mhawech-Fauceglia P, Wang, D, Kesterson, J, et al. Gene expressionprofiles in stage 1 uterine serous carcinoma in comparison to grade 3 and grade 1 stage 1 endometrioid adenocarcinoma. PloS One. 2011;6(3):e18066.
8. Suehiro Y, Umayahara, K, Ogata, H, et al. Genetic aberrations detected by comparative genomic hybridization predict outcome in patients with endometrioid carcinoma. Genes, Chromosomes & Cancer. 2000;29(1):75-82.
9. Rousseeuw PJ. Silhouettes: a graphical aid to the interpretation and validation of cluster analysis. J Comput Appl Math. 1987;20:53-65.
10. Subramanian A, Tamayo, P, Mootha, VK, et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545-15550.
11. Liu C, Li, Y, Semenov, M, et al. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell. 2002;108(6):837-847.
12. Mootha VK, Lindgren, CM, Eriksson, K, et al. PGC-1alpha-responsive genes invovled in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003;34(3):267-273.
13. He TC, Sparks, AB, Rago, C, et al. Identification of c-MYC as a target of the APC pathway. Science. 1998;281(5382):1509-1512.
14. Liang H, Cheung, LW, Li, J, et al. Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res. 2012;22(11):2120-2129.
15. McConechy MK, Ding, J, Cheang, M, et al. Use of mutation profiles to refine the classification of endometrial carcinomas. J of Pathology. 2012;228(1):20-30.
16. Peiro G, Peiro, FM, Ortiz-Martinez, F, et al. Association of mammalian target of rapamycin with aggressive type II endometrial carcinomas and poor outcome: a potential target treatment. Hum Pathol. 2013;44(2):218-225.
17. Klaus A, and Birchmeier, W Wnt signaling and its impact on development and cancer. Nat Rev Cancer. 2008;8(5):387-398.
18. Korinek V, Barker, N, Morin, PJ, et al. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/-colon carcinoma. Science. 1997;275(5307):1784-1787.
19. Chan TA, Wang, Z, Dang, LH, et al. Targted inactivation of CTNNB1 reveals unexpected effects of beta-catenin mutation. Proc Natl Acad Sci U S A. 2002;99(12):8265-8270.
20. Kanzawa M, Semba, S, Hara, S, et al. WNT5A is a key regulator of the epithelial-mesenchymal transition and cancer stem cell properties in human gastric carcinoma cells. Pathobiology. 2013;80(5):235-244.
21. Shelton DN, Fornalik, H, Neff, T, et al. The role of LEF1 in endometrial gland formation and carcinogenesis. PloS One. 2012;7(7):e40312.
22. TCGA. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330-337.
23. Zhou W, Lin, L, Majumdar, A, et al. Modulation of morphogenesis by noncanonical Wnt signaling requires ATF/CREB family-meidated transcriptional activation of TGFB2. Nat Genet. 2007;39(10):1225-1234.
24. Clevers H, and Nusse, R. Wnt/beta-catenin signaling and disease. Cell. 2012;149(6):1192-1205.
25. Shtutman M, Zhurinsky, J, Simcha, I, et al. The cyclin D1 gene is a target of the beta-catein/LEF-1 pathway. Proc Natl Acad Sci U S A. 1999;96(10):5522-5527.